NQMC Update Service: September 2, 2013 ► National Committee for Quality Assurance

NQMC Update Service: September 2, 2013

September 2, 2013

NQMC Update Service: September 2, 2013

Agency for Healthcare Research and Quality (AHRQ) sent this bulletin at 09/02/2013 01:10 PM EDT

September 2, 2013

New This Week

Measure Summaries

National Committee for Quality Assurance

• Adherence to antipsychotic medications for individuals with schizophrenia: percentage of members 19 to 64 years of age with schizophrenia during the measurement year who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of ACE inhibitors or ARBs during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Annual monitoring for members on angiotensin converting enzyme inhibitors or angiotensin receptor blockers. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of anticonvulsants during the measurement year and had at least one drug serum concentration level monitoring test for the prescribed drug in the measurement year. Annual monitoring for members on anticonvulsants. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of digoxin during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Annual monitoring for members on digoxin. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of diuretics during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Annual monitoring for members on diuretics. This updates a previously published measure summary.

• Antidepressant medication management (effective acute phase treatment): percentage of members 18 years of age and older with a diagnosis of major depression and were newly treated with antidepressant medication, and who remained on an antidepressant medication for at least 84 days (12 weeks). This updates a previously published measure summary.

• Antidepressant medication management (effective continuation phase treatment): percentage of members 18 years of age and older with a diagnosis of major depression and were newly treated with antidepressant medication, and who remained on an antidepressant medication for at least 180 days (6 months). This updates a previously published measure summary.

• Cardiovascular monitoring for people with cardiovascular disease and schizophrenia: percentage of members 18 to 64 years of age with schizophrenia and cardiovascular disease who had an LDL-C test during the measurement year.

• Diabetes monitoring for people with diabetes and schizophrenia: percentage of members 18 to 64 years of age with schizophrenia and diabetes who had both an LDL-C test and an HbA1c test during the measurement year.

• Diabetes screening for people with schizophrenia or bipolar disorder who are using antipsychotic medications: percentage of members 18 to 64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.

• Follow-up after hospitalization for mental illness: percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 30 days of discharge. This updates a previously published measure summary.

• Follow-up after hospitalization for mental illness: percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 7 days of discharge. This updates a previously published measure summary.

• Follow-up care for children prescribed ADHD medication (continuation and maintenance [C&M] phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended. This updates a previously published measure summary.

• Follow-up care for children prescribed ADHD medication (initiation phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase. This updates a previously published measure summary.

• Medication reconciliation post-discharge: percentage of discharges from January 1 to December 1 of the measurement year for members 66 years of age and older for whom medications were reconciled on or within 30 days of discharge. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a diagnosis of CRF and a prescription for nonaspirin NSAIDs or Cox-2 selective NSAIDs. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a diagnosis of dementia and a prescription for tricyclic antidepressants or anticholinergic agents. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a history of falls and a prescription for tricyclic antidepressants, antipsychotics or sleep agents. This updates a previously published measure summary.

• Use of high-risk medications in the elderly: percentage of Medicare members 66 years of age and older who received at least one high-risk medication. This updates a previously published measure summary.

• Use of high-risk medications in the elderly: percentage of Medicare members 66 years of age and older who received at least two different high-risk medications. This updates a previously published measure summary.